American ophthalmology had 4 buyer classes competing for practices in 2021. 3 of them are now functionally absent from the segment where most of the category's remaining opportunity actually sits. Understanding which buyer class is left, and why the others left, is the starting point for understanding which capital is positioned to absorb the next decade of ophthalmology succession.

The Strategic Corporate Threshold

The largest healthcare transactions of the last 18 months have flowed through pharmaceutical distributors, payers, and integrated health platforms rather than through traditional private equity sponsors. The mechanics are structurally distinct from PE consolidation. A strategic corporate buyer integrating a specialty platform into multi-billion-dollar distribution, specialty pharmacy, or value-based care infrastructure underwrites the acquisition against synergies measured at enterprise scale. Acquisition cost structures, integration overhead, and post-merger management requirements don't amortize across smaller ophthalmology transactions because the buyer's own infrastructure stack is built for platform-level deal sizes.

The functional threshold sits somewhere around $800 million in transaction value. The number isn't a stated policy at any specific acquirer. It's the emergent property of how strategic corporate infrastructure absorbs assets, and it defines what this buyer class can and cannot operationally reach. At the platform level, roughly 10 to 15 ophthalmology assets per year potentially clear the threshold, and almost all of them are existing PE-built platforms moving sponsor-to-strategic rather than independent practices arriving at the market for the first time. An independent practice generating $2 million in annual revenue does not register on the strategic corporate buyer map, and structural conditions don't exist under which it ever will.

The Sponsor-to-Sponsor Trap

The defining feature of the current healthcare private equity exit environment isn't deal volume but deal type. 74% of PE exits in the recent healthcare cohort flowed sponsor-to-sponsor rather than to strategic acquirers or public markets, per JAMA Health Forum research published in February 2025. Sponsor-to-sponsor exits compress returns on both sides of the transaction. The selling sponsor exits below the multiple originally underwritten at platform formation. The acquiring sponsor enters a platform already optimized for the previous fund cycle's exit thesis, which means the value-creation runway is shorter and the operational levers have already been pulled.

The downstream effect on ophthalmology practice succession is direct. Sponsors operating platforms in the back half of fund lifecycle reduce add-on acquisition velocity because the capital that would have funded bolt-on practices gets redirected toward debt service, portfolio stabilization, and exit preparation. The category's new platform formation rate has compressed in line with the broader healthcare specialist private equity fundraising environment, and even sponsors with available dry powder face platform-level economic constraints that prevent the aggressive roll-up posture that defined the 2017-2019 cohort.

The deeper reason this matters extends past the current cycle. The fund-cycle capital model assumes that platform value grows fast enough during the hold period to justify an exit multiple higher than the entry multiple, after fees, after debt service, and after the operational compression required to engineer the liquidity event. In ophthalmology, the model assumed a strategic corporate buyer or a public market would absorb the ophthalmology platforms when sponsors needed to exit. Both assumptions have weakened. Strategic corporates absorb only the largest ophthalmology platforms, and public markets have not opened for healthcare services platforms at meaningful scale. The class of capital that built the 2017-2019 ophthalmology cohort is increasingly constrained to selling platforms to itself at multiples that compress with each handoff, which is the structural reality of fund-cycle capital trying to absorb specialty healthcare assets that were never built for fund-cycle hold periods in the first place.

The Outpatient Mismatch

American hospital systems remain capital-constrained across physician employment broadly, but the structural reason hospitals stay absent from ophthalmology specifically predates the current retrenchment and won't reverse when the cycle turns. Hospital revenue models are built around occupied beds, procedural volume in hospital operating rooms, and the downstream utilization that follows admissions. Ophthalmology's surgical revenue runs through ambulatory surgery centers on procedural-time economics measured in minutes per case. Medical revenue runs through in-office procedures, intravitreal injections, and clinic-based diagnostic workflow. Hospital admissions tied to ophthalmologic conditions are rare and almost never generate the downstream utilization that drives hospital strategic planning.

The financial reality compounds the structural mismatch. American hospital operating margin median has sat around 1.3% across recent reporting periods. At that margin level, hospital systems cannot absorb sustained per-physician losses across specialties that don't drive inpatient utilization, which is why hospital ophthalmology employment never reached the levels seen in cardiology, oncology, or surgical subspecialties even during periods when hospital systems were aggressively expanding employed physician networks. The current retrenchment doesn't eliminate hospitals as ophthalmology buyers. It confirms an absence that was already permanent, and the absence won't reverse when the next hospital expansion cycle arrives because the underlying economics of ophthalmology haven't changed and won't.

What the Other 3 Buyer Classes Leave Behind

What remains after strategic corporates clear the top, private equity platforms manage portfolio rather than acquire aggressively, and hospital systems stay structurally absent? A segment of independent ophthalmology practices in the $1 to $4 million annual revenue range, owned by physicians moving through retirement and succession decisions across the next decade, sitting below every other buyer class's operational threshold. The succession volume across this segment is real and accelerating, and the buyer infrastructure to absorb it is not arriving from any of the 3 classes that historically would have been expected to.

This is where the category's future actually gets decided. American specialty healthcare was originally built on a model that worked for 100 years. Physicians owned their practices, practices passed from one generation of physicians to the next, and patient panels compounded across decades as the same physician saw the same families through children, parents, and grandparents.

Communities accumulated medical infrastructure as an inheritance rather than as an asset class.

The 2010-2024 arc broke that model at the level of who could own a community practice. Fund-cycle capital arrived, consolidated regional platforms, and exited into the next sponsor. Strategic corporates bought the largest platforms at the top. Hospitals retrenched. Solo practitioners aged into retirement with no successor and no buyer. What's being decided in the next decade isn't who owns the next generation of ophthalmology practices. It's whether American specialty healthcare runs through fund-cycle churn permanently or returns to the ownership structure that built the specialty in the first place.

The capital class structurally positioned to absorb this segment isn't an innovation. It's the class that existed before fund-cycle capital arrived in healthcare and will exist after it exits. Permanent-hold capital underwrites to cash-flow compounding across decades rather than exit value at year 5. The math works at $2 million in revenue because the structure doesn't carry the cost stack that requires $800 million. Practices acquired individually, held indefinitely, compounding cash flow without exit-cycle pressure to engineer liquidity events at predetermined intervals, run by successor physicians who own the clinical entity rather than employees on volume quotas. That model is what built American specialty healthcare, and it's what compounds capital reliably across the time horizons that matter to the family offices and ultra-high-net-worth principals who think in generations rather than fund vintages.

The Arithmetic of 2026

4 buyer classes existed in 2021. Strategic corporates now operate above $800 million. Private equity platforms manage portfolio rather than acquire aggressively because the exit math has tightened. Hospital systems stay structurally absent from a specialty that never fit their inpatient economics. That leaves permanent-capital operators as the only structurally viable buyer class for the sub-$10 million transactions where the next decade of ophthalmology succession deal flow actually runs.

What 4 buyer classes compressed to 1 represents is a structural restoration of the ownership model that built American specialty healthcare in the first place, this time operating at scale with institutional capital underwriting practices held the way they were originally built to be held.

What's being absorbed isn't an asset class. It's how a specialty serves the people who depend on it.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com